Pierre Moscovici, First President of the French Court of Auditors (“Cour des comptes,” the highest public finances authority in France), recently testified before the Senate Finance Committee (Commission des finances du Sénat). He expressed his views on a report of the financial institution of November 2020 advocating to reform the organic framework for laws provided by the Constitution, calling for strengthened governance of public finances.
This testimony could have a significant impact in the health sector, where innovative medicines may prove to be sources of savings in the medium or long term. In order to enable funding and access to innovative therapies, it is necessary to acknowledge that their health technology assessment must be multi-factorial and part of a multi-year funding trajectory. As the Court of Auditors pointed out at the Senate Finance Committee hearing, this trajectory will have to be based on more appropriate annual indicators, in particular with regard to the Ondam (the “National Health Insurance Expenditure Target,” or “Objectif national des dépenses d’assurance maladie”), which the Court of Auditors called incomplete.
We will continue to monitor these important developments in the French Court, and advocate for appropriate health technology assessments.
Authored by Charlotte Damiano and Jean-Baptiste Chagnon
New Doctrine of the French National Authority for Health
First steps towards taking into account the organizational impacts of health care technologies
Are you sure want to delete comment ?
Scan this QR Code to share this content
